Skip to content

The Effect of Vitamin D Supplementation in Overweight and Obese Pregnant Women

The Effect of Vitamin D Supplementation in Overweight and Obese Pregnant Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04841265
Enrollment
274
Registered
2021-04-12
Start date
2021-05-28
Completion date
2024-03-31
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Keywords

Vitamin D supplementation, Lipid profile, Vitamin D status, Birth outcomes, Pregnancy complications

Brief summary

To understand the role of vitamin D supplementation on pregnancy outcomes and metabolic status in overweight and obese pregnant women.

Detailed description

The effects of vitamin D supplementation on pregnancy outcomes and metabolic status of overweight and obese pregnant women remain uncertain. In particular, the dosage of vitamin D supplementation has not been defined in this high risk group of women. This study aims to examine whether oral supplement of vitamin D3 (cholecalciferol) in total dosage of 800 IU(prenatal multivitamin containing 400 IU vitamin D3 + 400 IU vitamin D3 alone) given to overweight and obese pregnant women since early pregnancy until delivery can improve maternal and neonatal outcomes, compared with those given prenatal multivitamin containing 400 IU vitamin D3 supplementation, a commonly given antenatal supplement in Singapore. The investigators' hypothesis is that higher dose vitamin D supplementation would lead to better outcomes in overweight and obese pregnant women. The investigators will conduct a two-arm, parallel non-blinded randomized controlled trial. Women with body mass index ≥25kg/m2 will be randomly assigned into groups with a 1:1 randomization ratio, receiving either 800 or 400 IU vitamin D3 supplementation. The study will be conducted at the antenatal clinics, KK Women's and Children's Hospital, Singapore. Measurements of serum 25-hydroxyvitamin D (25OHD), lipid profile and lifestyles information will be taken for all women at baseline (≤16 weeks gestation) and after three months of intervention (26-30 weeks gestation). All women will continue with the vitamin D3 supplementation until delivery. Primary outcomes include levels of maternal serum 25OHDconcentration and lipid profile at 26-30 gestation weeks as compared with the controls, adjusting for baseline measurements. Secondary outcomes include preeclampsia, gestational hypertension, gestational diabetes, glycaemic levels, caesarean section, gestational weight gain, preterm birth, low birth weight and small-for-gestational-age. This study will fill up the gap of knowledge regarding the role of vitamin D supplementation on pregnancy outcomes and metabolic status in overweight and obese pregnant women.

Interventions

DIETARY_SUPPLEMENTVitamin D3

The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.

Sponsors

KK Women's and Children's Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Gestation ≤16weeks (16 weeks + 6 days) upon intervention 2. Pre-pregnancy BMI ≥25 kg/m2 3. Aged 21-45 years 4. Willing and able to provide written, informed consent

Exclusion criteria

1. Having current or past hypo/hyperparathyroidism, hypercalciuria, hypercalcemia or osteomalacia 2. History of renal disease (including kidney stones and etc.), liver dysfunction, tuberculosis or sarcoidosis 3. Pre-existing diabetes mellitus or chronic hypertension 4. Taking lipid-lowering medicine 5. Gestational diabetes (as confirmed by oral glucose tolerance test) or gestational hypertensive disorder 6. Multiple pregnancy

Design outcomes

Primary

MeasureTime frame
Change in maternal serum 25OHD concentrationBaseline, 26-30 gestational weeks
Change in maternal total cholesterol levelBaseline, 26-30 gestational weeks
Change in maternal HDL-cholesterol levelBaseline, 26-30 gestational weeks
Change in maternal LDL-cholesterol levelBaseline, 26-30 gestational weeks
Change in maternal triglyceride levelBaseline, 26-30 gestational weeks

Secondary

MeasureTime frame
2-hour post-load glucose level24-28 gestational weeks
Incidence of caesarean sectionAt delivery
Incidence of preterm birth (<37 weeks)At delivery
Incidence of low birth weight (<2500g)At delivery
Incidence of preeclampsiaup to delivery
Neonatal birth length (cm)At delivery
Neonatal head circumference (cm)At delivery
Incidence of admission to special care (including intensive care) during neonatal periodWithin 28 days after delivery
Neonatal birth weight (g)At delivery
Incidence of gestational hypertensionThrough pregnancy until delivery
Incidence of gestational diabetesThrough pregnancy until delivery
Fasting glucose level24-28 gestational weeks
1-hour post-load glucose level24-28 gestational weeks

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026